GlassScriptPhysician profile
Seth M Hollander
NPI 1255451886
$16,355.46
in general payments reported to CMS, 2019-2025
43 companies · $4,469 in 2025
The $4,469 reported for 2025 was more than what 83% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $973 · 2020: $1,120 · 2021: $1,227 · 2022: $2,174 · 2023: $2,484 · 2024: $3,907 · 2025: $4,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,859 · Consulting Fee: $2,783 · Education: $188 · Travel and Lodging: $30.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,859.11 |
| Consulting Fee | $2,783.20 |
| Education | $187.53 |
| Travel and Lodging | $30.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,476.21 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,116.71 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,970.41 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,418.62 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,213.42 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Csl Behring | $552.27 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $523.07 | 2019-2025 | |
| Kaleo, INC. | $487.84 | 2019-2024 | Auvi-Q |
| Octapharma USA, INC. | $388.55 | 2019-2025 | Panzyga, Cutaquig |
| Biocryst US Sales Co., LLC | $307.97 | 2021-2025 | Orladeyo |
| Amgen INC. | $303.87 | 2022-2025 | Tezspire |
| Pharming Healthcare, INC. | $243.60 | 2019-2025 | Ruconest |
| Jubilant Hollisterstier LLC | $225.46 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $218.53 | 2025 | Neffy |
| Pfizer INC. | $209.78 | 2019-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $205.91 | 2019-2025 | Xolair |
| Alk-Abello, INC | $178.06 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Galderma Laboratories, L.P. | $150.19 | 2025 | Nemluvio |
| Abbvie INC. | $131.38 | 2021-2022 | |
| Optinose US, INC. | $81.61 | 2022-2023 | |
| Hikma Pharmaceuticals USA | $80.96 | 2023-2024 | Ryaltris |
| Leo Pharma INC. | $79.81 | 2024 | Adbry |
| Grifols USA, LLC | $79.36 | 2021-2024 | Xembify |
| Organon LLC | $72.39 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $71.76 | 2020-2021 | |
| Incyte Corporation | $66.26 | 2021-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $61.99 | 2023 | |
| Azurity Pharmaceuticals, INC. | $52.51 | 2025 | Alvesco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.06 | 2019-2021 | |
| Hospira, INC. | $48.63 | 2024-2025 | |
| Shire North American Group INC | $40.59 | 2019 | |
| Kedrion Biopharma, INC. | $37.04 | 2024 | Gammaked, Kedrab, Koate |
| Biocryst Pharmaceuticals, INC. | $34.08 | 2020 | |
| Aytu Biopharma, INC. | $32.01 | 2024-2025 | Karbinal |
| Lilly USA, LLC | $22.00 | 2024 | |
| Blue Earth Diagnostics | $21.92 | 2025 | Posluma |
| Blueprint Medicines Corporation | $18.26 | 2024 | Ayvakit |
| Aimmune Therapeutics, INC. | $17.93 | 2022 | |
| Phadia US INC. | $17.31 | 2024 | Immunocap |
| Adma Biomanufacturing LLC | $17.20 | 2024 | |
| Paratek Pharmaceuticals, INC. | $16.21 | 2025 | Xhance |
| Cycle Pharmaceuticals INC | $8.94 | 2024 | Sajazir |
| Electromed, INC. | $5.78 | 2024 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Hollander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.